Oral GLP-1 medications

Which oral GLP-1 medications are FDA-approved?

Three oral semaglutide tablets are FDA-approved: Rybelsus and Ozempic tablets, both indicated for adults with type 2 diabetes on one shared label, and the Wegovy pill, indicated for chronic weight management on the Wegovy label [1][2]. All are taken once daily on an empty stomach with up to 4 ounces of water, swallowed whole, and require waiting at least 30 minutes before eating or taking other oral medications [1][2].

Is there an oral GLP-1 that is not semaglutide?

Yes. Foundayo (orforglipron), made by Eli Lilly, is a GLP-1 receptor agonist tablet with initial U.S. approval in 2026. Its label indicates it, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus at least one weight-related comorbid condition [3]. It is taken once daily with or without food, swallowed whole, and the label advises against use with another GLP-1 receptor agonist [3].

How do oral GLP-1s differ from injections?

The semaglutide tablets are taken once a day, while the Wegovy and Ozempic injections are dosed once a week [1][2]. Tablets and injections alike escalate through several strength steps before reaching a maintenance dose [1][2]. Strength numbering isn't shared across dosage forms on the same label, so a tablet milligram amount doesn't equal an injection milligram amount [1][2].